- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04147000
Pharmacokinetics and Pharmacodynamics of Oral Sertraline Before and After Bariatric Surgery (ANTILOP)
Pharmacokinetics and Pharmacodynamics of Oral Sertraline Before and After Bariatric Surgery; a Prospective Open Observational Study
Study Overview
Status
Conditions
Detailed Description
The pharmacokinetic changes of sertraline after bariatric surgery are studied by assessing the exposition for sertraline in individuals with long term treatment by measuring the area under the curve (AUC0-τ) 8 weeks before and one, six and twelve months after bariatric surgery in 30 participants.
The effect of variation of sertraline concentration is studied by a psychiatric assessment of depressive symptoms and symptoms of anxiety disorder. The aim ist to study if there is a relation between changes in pharmacokinetics and effect of sertraline after bariatric surgery.
For the assessment of side effects a self-reporting scale is used. These participants are recruited consequentially with the aim to get equal numbers of patients with both most usual types of surgery in Sweden (laparoscopic RYGB and gastric sleeve).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Örebro
-
Lindesberg, Örebro, Sweden, 71135
- Lindesbergs lasarett
-
-
Östergötland
-
Norrköping, Östergötland, Sweden, 60379
- Vrinnevisjukhus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- scheduled to undergo either gastric bypass or gastric sleeve surgery via surgeon clinics in Örebro or Norrköping
- prescription of sertraline
- since at least one month
- planned to be continued at the time of inclusion
- swedish speaking
Exclusion Criteria:
- comorbidity with the consequence that the potential participant may not be able to complete the study
- if participation should result in a high risk for patients health or safety
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Area under the concentration curve of sertraline
Time Frame: 8 weeks before, 1, 6 and 12 month after bariatric surgery before sertraline intake and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 24 hours post dose
|
Changes in the area under sertraline serum concentration vs time curve (AUC(0-t))
|
8 weeks before, 1, 6 and 12 month after bariatric surgery before sertraline intake and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 24 hours post dose
|
|
Change in Clinical Anxiety Scale
Time Frame: 8 weeks before, 1, 6 and 12 month after bariatric surgery
|
Psychiatric assessment of symptoms of anxiety disorders with an 5-items-scale (Psychic tension, Ability to relax/muscular tension, Startle response/hyperarousability, Worrying, Apprehension).
Every item has values between 0 (no symptoms) and 4 (marked symptoms).
The overall score ranges from 0 to 20.Higher scores indicate higher anxiety symptoms.
|
8 weeks before, 1, 6 and 12 month after bariatric surgery
|
|
Change in Montgomery-Åsberg-depression rating scale (MADRS-B)
Time Frame: 8 weeks before, 1, 6 and 12 month after bariatric surgery
|
Assessment of depressive symptoms with a 10-items scale (Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, Suicidal Thoughts).
Higher score indicates more depressive symptoms, each item spans over a score from 0 to 6; the overall score ranges from 0 to 60.
|
8 weeks before, 1, 6 and 12 month after bariatric surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the area under concentration vs time curve of desmethylsertraline
Time Frame: 8 weeks before, 1, 6 and 12 month after bariatric surgerybefore sertraline intake and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 24 hours post dose
|
Changes in the area under concentration vs time curve of desmethylsertraline
|
8 weeks before, 1, 6 and 12 month after bariatric surgerybefore sertraline intake and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 24 hours post dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Andresen, MD, Linkoping university, Örebro university
- Study Director: Ylva Böttiger, Professor, Linkoeping University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANTILOP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.